Figure 5. Lovastatin in combination with VEGFR-2 TKIs inhibits ligand induced activation of AKT, S6K1 and 4EBP1.

Control cells were serum starved for 24 hr followed by 2 hr treatments with either 10 µM KRN633, 10 nM rapamycin, 5 µM lovastatin or their combinations. All cells were then lysed after stimulation with 50 ng/ml VEGF₁₆₅ for 30 min. Results demonstrated that lovastatin in combination with KRN633 induced the most significant decrease in phosphorylation status of all three proteins in H28 cells. Expression levels of total AKT, S6K1 and 4EBP1 were assayed as loading controls.